文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

在百万退伍军人计划中使用传统风险因素和多基因风险评分进行心血管疾病风险评估。

Cardiovascular Disease Risk Assessment Using Traditional Risk Factors and Polygenic Risk Scores in the Million Veteran Program.

机构信息

Veterans Affairs Boston Healthcare System, Boston, Massachusetts.

Department of Medicine, Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts.

出版信息

JAMA Cardiol. 2023 Jun 1;8(6):564-574. doi: 10.1001/jamacardio.2023.0857.


DOI:10.1001/jamacardio.2023.0857
PMID:37133828
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10157509/
Abstract

IMPORTANCE: Primary prevention of atherosclerotic cardiovascular disease (ASCVD) relies on risk stratification. Genome-wide polygenic risk scores (PRSs) are proposed to improve ASCVD risk estimation. OBJECTIVE: To determine whether genome-wide PRSs for coronary artery disease (CAD) and acute ischemic stroke improve ASCVD risk estimation with traditional clinical risk factors in an ancestrally diverse midlife population. DESIGN, SETTING, AND PARTICIPANTS: This was a prognostic analysis of incident events in a retrospectively defined longitudinal cohort conducted from January 1, 2011, to December 31, 2018. Included in the study were adults free of ASCVD and statin naive at baseline from the Million Veteran Program (MVP), a mega biobank with genetic, survey, and electronic health record data from a large US health care system. Data were analyzed from March 15, 2021, to January 5, 2023. EXPOSURES: PRSs for CAD and ischemic stroke derived from cohorts of largely European descent and risk factors, including age, sex, systolic blood pressure, total cholesterol, high-density lipoprotein (HDL) cholesterol, smoking, and diabetes status. MAIN OUTCOMES AND MEASURES: Incident nonfatal myocardial infarction (MI), ischemic stroke, ASCVD death, and composite ASCVD events. RESULTS: A total of 79 151 participants (mean [SD] age, 57.8 [13.7] years; 68 503 male [86.5%]) were included in the study. The cohort included participants from the following harmonized genetic ancestry and race and ethnicity categories: 18 505 non-Hispanic Black (23.4%), 6785 Hispanic (8.6%), and 53 861 non-Hispanic White (68.0%) with a median (5th-95th percentile) follow-up of 4.3 (0.7-6.9) years. From 2011 to 2018, 3186 MIs (4.0%), 1933 ischemic strokes (2.4%), 867 ASCVD deaths (1.1%), and 5485 composite ASCVD events (6.9%) were observed. CAD PRS was associated with incident MI in non-Hispanic Black (hazard ratio [HR], 1.10; 95% CI, 1.02-1.19), Hispanic (HR, 1.26; 95% CI, 1.09-1.46), and non-Hispanic White (HR, 1.23; 95% CI, 1.18-1.29) participants. Stroke PRS was associated with incident stroke in non-Hispanic White participants (HR, 1.15; 95% CI, 1.08-1.21). A combined CAD plus stroke PRS was associated with ASCVD deaths among non-Hispanic Black (HR, 1.19; 95% CI, 1.03-1.17) and non-Hispanic (HR, 1.11; 95% CI, 1.03-1.21) participants. The combined PRS was also associated with composite ASCVD across all ancestry groups but greater among non-Hispanic White (HR, 1.20; 95% CI, 1.16-1.24) than non-Hispanic Black (HR, 1.11; 95% CI, 1.05-1.17) and Hispanic (HR, 1.12; 95% CI, 1.00-1.25) participants. Net reclassification improvement from adding PRS to a traditional risk model was modest for the intermediate risk group for composite CVD among men (5-year risk >3.75%, 0.38%; 95% CI, 0.07%-0.68%), among women, (6.79%; 95% CI, 3.01%-10.58%), for age older than 55 years (0.25%; 95% CI, 0.03%-0.47%), and for ages 40 to 55 years (1.61%; 95% CI, -0.07% to 3.30%). CONCLUSIONS AND RELEVANCE: Study results suggest that PRSs derived predominantly in European samples were statistically significantly associated with ASCVD in the multiancestry midlife and older-age MVP cohort. Overall, modest improvement in discrimination metrics were observed with addition of PRSs to traditional risk factors with greater magnitude in women and younger age groups.

摘要

重要性:动脉粥样硬化性心血管疾病(ASCVD)的一级预防依赖于风险分层。全基因组多基因风险评分(PRS)被提议用于改善 ASCVD 风险估计。 目的:确定冠状动脉疾病(CAD)和急性缺血性中风的全基因组 PRS 是否可以在一个具有多种祖先的中年人群中改善传统临床危险因素的 ASCVD 风险估计。 设计、地点和参与者:这是一项回顾性队列研究的预后分析,从 2011 年 1 月 1 日至 2018 年 12 月 31 日进行了事件的发病分析。纳入了 MVP(百万退伍军人计划)中的成年人,这些人在基线时无 ASCVD 且未使用他汀类药物,是一个拥有来自大型美国医疗保健系统的遗传、调查和电子健康记录数据的大型生物库。数据于 2021 年 3 月 15 日至 2023 年 1 月 5 日进行分析。 暴露因素:CAD 和缺血性中风的 PRS 源自主要为欧洲血统的队列和危险因素,包括年龄、性别、收缩压、总胆固醇、高密度脂蛋白胆固醇、吸烟和糖尿病状况。 主要结局和测量指标:非致命性心肌梗死(MI)、缺血性中风、ASCVD 死亡和复合 ASCVD 事件的发生。 结果:共纳入了 79151 名参与者(平均[标准差]年龄 57.8[13.7]岁;68503 名男性[86.5%])。该队列包括以下经过协调的遗传和种族分类的参与者:18505 名非西班牙裔黑人(23.4%)、6785 名西班牙裔(8.6%)和 53861 名非西班牙裔白人(68.0%),中位(5 至 95 百分位数)随访时间为 4.3(0.7-6.9)年。从 2011 年到 2018 年,观察到 3186 例 MI(4.0%)、1933 例缺血性中风(2.4%)、867 例 ASCVD 死亡(1.1%)和 5485 例复合 ASCVD 事件(6.9%)。CAD PRS 与非西班牙裔黑人(危险比[HR],1.10;95%置信区间[CI],1.02-1.19)、西班牙裔(HR,1.26;95%CI,1.09-1.46)和非西班牙裔白人(HR,1.23;95%CI,1.18-1.29)参与者的 MI 发病相关。中风 PRS 与非西班牙裔白人参与者的中风发病相关(HR,1.15;95%CI,1.08-1.21)。CAD 加中风联合 PRS 与非西班牙裔黑人(HR,1.19;95%CI,1.03-1.17)和非西班牙裔(HR,1.11;95%CI,1.03-1.21)参与者的 ASCVD 死亡相关。联合 PRS 也与所有祖裔群体的 ASCVD 复合事件相关,但在非西班牙裔白人群体中(HR,1.20;95%CI,1.16-1.24)比非西班牙裔黑人(HR,1.11;95%CI,1.05-1.17)和西班牙裔(HR,1.12;95%CI,1.00-1.25)参与者中更为显著。在男性(5 年风险>3.75%,0.38%;95%CI,0.07%-0.68%)、女性(6.79%;95%CI,3.01%-10.58%)、年龄大于 55 岁(0.25%;95%CI,0.03%-0.47%)和年龄 40 至 55 岁(1.61%;95%CI,-0.07%至 3.30%)的中危人群中,加入 PRS 后对传统风险模型的净重新分类改善程度适中。 结论和相关性:研究结果表明,主要源自欧洲样本的 PRS 与 MVP 中多种祖裔的中年和老年人群的 ASCVD 统计学显著相关。总体而言,随着 PRS 加入传统危险因素,区分度指标适度提高,女性和年轻年龄组的幅度更大。

相似文献

[1]
Cardiovascular Disease Risk Assessment Using Traditional Risk Factors and Polygenic Risk Scores in the Million Veteran Program.

JAMA Cardiol. 2023-6-1

[2]
Predictive Utility of a Coronary Artery Disease Polygenic Risk Score in Primary Prevention.

JAMA Cardiol. 2023-2-1

[3]
Association of polygenic risk scores with incident atherosclerotic cardiovascular disease events among individuals with coronary artery calcium score of zero: The multi-ethnic study of atherosclerosis.

Prog Cardiovasc Dis. 2022

[4]
Long-Term Body Mass Index Variability and Adverse Cardiovascular Outcomes.

JAMA Netw Open. 2024-3-4

[5]
Cardiovascular Risk Associated With Social Determinants of Health at Individual and Area Levels.

JAMA Netw Open. 2024-4-1

[6]
Prevalence of Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and 10-Year Disease Risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020.

JAMA Cardiol. 2023-5-1

[7]
Coronary heart disease and ischemic stroke polygenic risk scores and atherosclerotic cardiovascular disease in a diverse, population-based cohort study.

PLoS One. 2023

[8]
Combining European and U.S. risk prediction models with polygenic risk scores to refine cardiovascular prevention: the CoLaus|PsyCoLaus Study.

Eur J Prev Cardiol. 2023-5-9

[9]
Association of Coronary Artery Calcium Score vs Age With Cardiovascular Risk in Older Adults: An Analysis of Pooled Population-Based Studies.

JAMA Cardiol. 2017-9-1

[10]
Assessment of Coronary Artery Calcium Scoring to Guide Statin Therapy Allocation According to Risk-Enhancing Factors: The Multi-Ethnic Study of Atherosclerosis.

JAMA Cardiol. 2021-10-1

引用本文的文献

[1]
Impact of genetic risk and lifestyles on cardiovascular disease-free and total life expectancy: a cohort study.

Genome Med. 2025-7-22

[2]
Role of Genetics in Early-Onset Cardiovascular Disease.

Cureus. 2025-6-14

[3]
An Evidence Map of the Women Veterans' Health Literature, 2016 to 2023: A Systematic Review.

JAMA Netw Open. 2025-4-1

[4]
Meta-prediction of coronary artery disease risk.

Nat Med. 2025-4-16

[5]
Utilization of polygenic risk scores in drug development protocols.

Pharmacogenomics. 2025

[6]
A landmark federal interagency collaboration to promote data science in health care: Million Veteran Program-Computational Health Analytics for Medical Precision to Improve Outcomes Now.

JAMIA Open. 2024-11-6

[7]
Application of polygenic scores to a deeply phenotyped sample enriched for substance use disorders reveals extensive pleiotropy with psychiatric and somatic traits.

Neuropsychopharmacology. 2024-12

[8]
Protein Identification for Stroke Progression via Mendelian Randomization in Million Veteran Program and UK Biobank.

Stroke. 2024-8

[9]
Long-Term Body Mass Index Variability and Adverse Cardiovascular Outcomes.

JAMA Netw Open. 2024-3-4

[10]
Selection, optimization and validation of ten chronic disease polygenic risk scores for clinical implementation in diverse US populations.

Nat Med. 2024-2

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索